Latest Conference Articles

LY4052031 demonstrated promising clinical activity after disease progression on enfortumab vedotin in metastatic urothelial carcinoma.

Adjuvant durvalumab plus tremelimumab significantly improved DFS vs active monitoring in both high- and intermediate-risk resected RCC.

Mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed or refractory multiple myeloma.

Relacorilant plus nab-paclitaxel displayed OS benefit irrespective of prior taxane exposure or taxane-free interval in platinum-resistant ovarian cancer.

Results from the phase 3 MajesTEC-9 trial show superior PFS, OS, and ORR outcomes with teclistamab monotherapy in pretreated relapsed/refractory myeloma.

The phase 3 WU-KONG28 data showed that first-line sunvozertinib improved PFS and ORR vs chemotherapy in EGFR exon 20–mutant NSCLC.

Extended follow-up data from NRG-GY018 show a sustained OS benefit with pembrolizumab plus chemotherapy regardless of MMR status or post-study ICI therapy.

Final analysis of DREAMM-9 shows promising efficacy data and an optimal dosing schedule for BVRd in transplant-ineligible newly diagnosed multiple myeloma.

Chiauranib plus weekly paclitaxel cut the risk of progression or death by 57% vs placebo plus paclitaxel in platinum-resistant or refractory ovarian cancer.

The combination cut the risk of progression or death by 65% in the first phase 3 trial of an ADC plus pembrolizumab in this setting.

Amivantamab plus lazertinib led to a median OS of 41.0 months in EGFR-mutated advanced NSCLC.

Long-term follow-up from the RUBY trial showed few progression events and potential for curative intent in dMMR/MSI-H endometrial cancer.

At the 2026 ASCO Annual Meeting, results from the 7-year update of the phase 3 CROWN study were presented.

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

Ajai Chari, MD, discusses treatment navigation in relapsed/refractory multiple myeloma in the era of CAR T-cell therapies and bispecific antibodies.

Poll results reflected some of the most anticipated presentations and fields of interest in hematologic oncology at the 2026 ASCO Annual Meeting.

Poll results reflect some of the most anticipated presentations and fields of interest in gynecologic oncology at the 2026 ASCO Annual Meeting.

Ahead of the 2026 ASCO Annual Meeting, results from the phase 3 FIGHT-302 study have been announced.

Biomarker analyses indicate that CD47 expression may help predict benefit from zanidatamab plus evorpacept in HER2-positive metastatic breast cancer.

Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.

Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.

Tycel Phillips, MD, discusses considerations for navigating treatment options in relapsed/refractory mantle cell lymphoma.

Thomas J. Polascik, MD, discusses findings from a study of an AI-based VOC assay for prostate cancer detection.

Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC.

In an indirect comparison, NAI+BCG showed numerically higher, significantly longer responses and a trend toward greater bladder preservation vs nadofaragene.

Enzalutamide plus radium-223 demonstrated no early survival advantage but an 80% death risk reduction for long-term survivors in mCRPC at over 60 months.

Rucaparib showed a manageable and consistent safety profile in patients with BRCA-mutated prostate cancer.

No new safety signals were identified, and imAEs were predominantly low-grade and consistent with the known durvalumab safety profile.

Fred Saad, MD, CQ, FRCS, FCAHS, discusses PSA end point data from the PSMAddition study in PSMA+ mHSPC

Adding lutetium Lu 177 vipivotide tetraxetan to ADT and ARPI deepened PSA responses and reduced the risk of PSA progression by 58% in patients with mHSPC.